查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433330

2023-2030 年全球融合切片市场

Global Fusion Biopsy Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

预计全球融合活检市场在预测期内（2023-2030）将以 8.4% 的CAGR成长。融合活检是一种微创手术，结合磁振造影 (MRI) 和超音波技术来引导前列腺可疑区域的活检。此程序用于诊断前列腺癌，这是全世界男性最常见的癌症。市场主要参与者都致力于在市场上引入新技术，以实现更好的先进医疗和诊断。例如，2023 年 7 月，FUJIFILM Healthcare Europe 推出了 ARIETTA 65 IntuitiveFusion，这是一种具有专用前列腺融合成像功能的诊断超音波系统，可帮助泌尿科医生简化活检。 FUJIFILM Healthcare Europe 最近在荷兰阿姆斯特丹举行的欧洲泌尿外科协会 (EAU) 大会上推出了 ARIETTA 65 IntuitiveFusion。此紧凑型系统由独特的超音波引擎和整合融合软体提供动力，可对目标前列腺活检进行立体定向导航。

细分市场前景

全球融合活检市场按活检途径和最终用户进行细分。根据切片途径，市场分为经直肠切片和经会阴切片检查。根据最终用户，市场分为医院、诊断中心和门诊护理中心。在最终用户中，由于购买力较高，预计医院细分市场将占据相当大的市场份额。融合活检系统的平均单价较高，私人诊断中心难以负担。

预计经直肠细分市场将在全球融合活检市场中占据相当大的份额

在活检途径中，经直肠子细分市场预计将在全球融合活检市场中占据相当大的份额。这种节段性生长归因于透过直肠进行的过程。这是最常见的融合活检类型，因为它可以轻鬆进入前列腺。此外，它具有较低的感染风险和较短的手术时间，使其更适合使用。这导致该活检路线的策略性倡议增加，市场参与者正专注于开发新的和改进的产品。例如，2023 年 1 月，Bannerghatta 路的 Fortis 医院宣布推出 BK 超音波 MRI 融合活检解决方案，改变了前列腺癌诊断和治疗的游戏规则。机器人辅助手术是一种微创手术，可以让外科医生在进行手术时拥有更好的视野、精确度和控制力。其他好处包括减轻疼痛、减少术后感染和减少疤痕。恢復迅速，住院时间最短，活动和復原速度更快。减少感染机会使其成为糖尿病和其他合併症患者的理想手术。

区域展望

全球融合活检市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本） 、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于该地区前列腺癌盛行率不断上升，预计欧洲将在全球市场中占据显着份额。根据英国前列腺癌协会的数据，平均每年有超过 52,000 名男性被诊断出患有前列腺癌，即每天有 144 名男性被诊断出患有前列腺癌。每 45 分钟就有一名男性死于摄护腺癌，也就是说每年有超过 12,000 名男性死于摄护腺癌。

北美地区全球融合活检市场预计将以显着的CAGR成长

在所有地区中，北美地区预计在预测期内将以相当大的CAGR成长。区域成长归因于新产品的推出、现有业务的扩张、前列腺癌意识的提高、人口基数的增加以及该地区可支配收入水准的提高。根据美国国家癌症研究所的数据，每年每 10 万名男性中有 113.4 例前列腺癌新病例。每年每 10 万名男性中有 18.8 人死亡。根据 2017-2019 年的资料，大约 12.9% 的男性将在一生中的某个时刻被诊断出患有前列腺癌。 2020 年，美国估计有 3,343,976 名男性罹患摄护腺癌。因此，市场参与者不断在该地区推出用于癌症治疗的新产品。例如，2023 年 6 月，Hoag 推出了 Focal One（一种非侵入性机器人高强度聚焦超音波 (HIFU) 技术），为患有局限性前列腺癌的男性提供了一种与疾病作斗争的额外治疗选择。 HIFU 是一种精确针对癌性前列腺组织的先进技术，使泌尿科医生能够仅消融或破坏前列腺的患病部分。结果是癌症治疗没有治疗整个前列腺所带来的许多副作用，包括泌尿和勃起副作用。

市场参与者展望

服务于融合活检市场的主要公司包括 Eigen Health、ESAOTE SpA、Focal Healthcare、GeoScan Medical、Hitachi Ltd.、KOELIS、Koninklijke Philips NV、MedCom、UC-Care Medical Systems Ltd. 等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2022 年 8 月，Promaxo, Inc. 宣布已与欧洲领先的大学医院、伦敦帝国学院和德国图宾根大学医院开展 MR 引导前列腺干预研究合作。 Promaxo 与伦敦帝国学院合作，获得了一笔资助并签订了一项临床研究协议，该研究比较 Promaxo 的便携式 MRI 和 TRUS-Fusion 活检，以评估前列腺癌检测的准确性。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 在全球融合活检市场中运作的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • ESAOTE SpA
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Koninklijke Philips NV
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • UC-Care Medical Systems Ltd.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按活检路线分類的全球融合活检市场
    • 经直肠
    • 经会阴
  • 按最终用途分類的全球融合活检市场
    • 医院
    • 诊断中心
    • 门诊护理中心

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Eigen Health
  • Focal Healthcare
  • GeoScan Medical
  • Hitachi Ltd.
  • innoMedicus Ltd
  • KOELIS
  • MEDCOM Sp. z o. o
Product Code: OMR2028004

Global Fusion biopsy Market Size, Share & Trends Analysis Report by Biopsy Route (Transrectal and Transperineal), and by End User (Hospitals, Diagnostic Centers and Ambulatory Care Centers), Forecast Period (2023-2030)

The global fusion biopsy market is anticipated to grow at a CAGR of 8.4% during the forecast period (2023-2030). Fusion biopsy is a minimally invasive procedure that uses a combination of magnetic resonance imaging (MRI) and ultrasound technology to guide the biopsy of suspicious areas in the prostate gland. This procedure is used to diagnose prostate cancer, which is the most common cancer among men worldwide. The major players in the market are focusing on introducing new technology in the market for better advanced medical treatment and diagnosis. For instance, in July 2023, FUJIFILM Healthcare Europe unveiled the ARIETTA 65 IntuitiveFusion, a diagnostic ultrasound system with dedicated prostate fusion imaging to help urologists streamline biopsies. FUJIFILM Healthcare Europe launched the ARIETTA 65 IntuitiveFusion at the recent European Association of Urology (EAU) congress in Amsterdam, the Netherlands. This compact system is powered by ultrasound unique engine and integrated fusion software to allow stereotactic navigation of targeted prostate biopsies.

Segmental Outlook

The global fusion biopsy market is segmented on the biopsy route, and end user. Based on the biopsy route, the market is sub-segmented into transrectal and transperineal. Based on the end user, the market is sub-segmented into hospitals, diagnostic centers and ambulatory care centers. Among the end-user, the hospital sub-segment is anticipated to hold a considerable share of the market, owing to high purchasing power. The average unit price of a fusion biopsy system is high, making it unaffordable for private diagnostic centers.

The Transrectal Sub-Segment is Anticipated to Hold a Considerable Share of the Global Fusion biopsy Market

Among the biopsy route, the transrectal sub-segment is expected to hold a considerable share of the global Fusion biopsy market. This segmental growth is attributed to factor includes, the process performed through the rectum. This is the most common type of fusion biopsy, as it allows for easy access to the prostate gland. Also, it has lower risk of infection and shorter procedure time which make it more suitable to use. It lead to increase in strategic initiatives for this Biopsy Route and market players are focusing on developing new and improved products. For instance, in January 2023, Fortis Hospital, Bannerghatta Road announced the launch of BK ultrasound MRI Fusion Biopsy solution, a game changer in Prostate cancer diagnosis and treatment. Robot-aided surgery is a minimally invasive procedure which allows surgeons to have better vision, precision, and control while performing the surgeries. Other benefits include decreased pain, fewer post-operative infections and less scarring. Recovery is rapid, with minimal hospital stay, faster mobilization and rehabilitation. Reducing the chance of infection makes it an ideal procedure for people with diabetes and other co-morbidities.

Regional Outlook

The global fusion biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to rising prevalence of prostate cancer in the region. According to Prostate Cancer UK, more than 52,000 men are diagnosed with prostate cancer every year on average - that is 144 men every day. Every 45 minutes one man dies from prostate cancer - that is more than 12,000 men every year.

The North America Region is Expected to Grow at a Significant CAGR in the Global Fusion biopsy Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to new product launches, expansion of already existing business, rising awareness of prostate cancer, increasing population base, and rising disposable income levels in the region. According to National Cancer Institute, the rate of new cases of prostate cancer was 113.4 per 100,000 men per year. The death rate was 18.8 per 100,000 men per year. Approximately 12.9 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2017- 2019 data. In 2020, there were an estimated 3,343,976 men living with prostate cancer in the United States. Hence, the market players are continuously introducing new product for cancer treatment in the region. For instance, in June 2023, Hoag is giving men with localized prostate cancer an additional treatment option in the battle against disease with the introduction of Focal One, a non-invasive robotic High Intensity Focused Ultrasound (HIFU) technology. An advanced technology that precisely targets cancerous prostate tissue, HIFU allows urologic surgeons to ablate, or destroy, just the diseased portion of the prostate. The result is a cancer treatment without many of the side effects that come with treating the entire prostate, including urinary and erectile side effects.

Market Players Outlook

The major companies serving the fusion biopsy market include Eigen Health, ESAOTE SpA, Focal Healthcare, GeoScan Medical, Hitachi Ltd., KOELIS, Koninklijke Philips N.V., MedCom, UC-Care Medical Systems Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In August 2022, Promaxo, Inc. announced it has entered into research collaborations with leading European university hospitals, Imperial College London and University Hospital Tuebingen Germany, for MR guided prostate interventions. In collaboration with Imperial College London, Promaxo received a grant and entered into a research agreement for a clinical study comparing Promaxo's portable MRI and TRUS-Fusion biopsy to assess for accuracy in prostate cancer detection.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global fusion biopsy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. ESAOTE SpA
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Koninklijke Philips N.V.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. UC-Care Medical Systems Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Fusion biopsy Market by Biopsy Route
    • 4.1.1. Transrectal
    • 4.1.2. Transperineal
  • 4.2. Global Fusion biopsy Market by End-use
    • 4.2.1. Hospitals
    • 4.2.2. Diagnostic Centers
    • 4.2.3. Ambulatory Care Centers

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Eigen Health
  • 6.2. Focal Healthcare
  • 6.3. GeoScan Medical
  • 6.4. Hitachi Ltd.
  • 6.5. innoMedicus Ltd
  • 6.6. KOELIS
  • 6.7. MEDCOM Sp. z o. o

LIST OF TABLES

  • 1. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 2. GLOBAL TRANSRECTAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL TRANSPERINEAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 4. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 5. GLOBAL FUSION BIOPSY FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL FUSION BIOPSY FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL FUSION BIOPSY FOR AMBULATORY CARE CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 10. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 11. NORTH AMERICAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 12. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 13. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 14. EUROPEAN FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 15. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 17. ASIA-PACIFIC FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 18. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY BIOPSY ROUTE, 2022-2030 ($ MILLION)
  • 20. REST OF THE WORLD FUSION BIOPSY MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL FUSION BIOPSY MARKET SHARE BY BIOPSY ROUTE, 2022 VS 2030 (%)
  • 2. GLOBAL TRANSRECTAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL TRANSPERINEAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL FUSION BIOPSY MARKET SHARE BY END-USE, 2022 VS 2030 (%)
  • 5. GLOBAL FUSION BIOPSY FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL FUSION BIOPSY FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL FUSION BIOPSY FOR AMBULATORY CARE CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL FUSION BIOPSY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. US FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 10. CANADA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 11. UK FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. FRANCE FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. GERMANY FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. ITALY FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. SPAIN FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. REST OF EUROPE FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. INDIA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CHINA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. JAPAN FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. SOUTH KOREA FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF ASIA-PACIFIC FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF THE WORLD FUSION BIOPSY MARKET SIZE, 2022-2030 ($ MILLION)